Nocturnal Enuresis Clinical Trial
Official title:
A Comparative Crossover Study on the Safety, Efficacy, and Patient Quality of Life Comparing PureWick™ System With an Established Comparator in the Home Setting for Incontinence Overnight
In this prospective, post-market, multi-site, open-label, crossover trial, women with urinary incontinence requiring the use of diapers (changes complets (French term)) at night will be 1:1 randomized to a treatment sequence using two devices (PureWick™ System and Hollister® Female Urinary Pouch External Collection Device) and followed for approximately 10 weeks through 2 treatment phases. The primary objectives are to evaluate safety (skin injury) and efficacy (capture rate). Safety will be assessed using the Draize Scale and efficacy will be measured based on daily urine capture rate.
In this prospective, post-market, multi-site, open-label, crossover trial, women with urinary incontinence requiring the use of diapers (changes complets (French term)) at night will be 1:1 randomized to a treatment sequence using two devices (PureWick™ System and Hollister® Female Urinary Pouch External Collection Device) and followed for approximately 10 weeks through 2 treatment phases. Approximately 30 female participants from 2 sites will be enrolled into the study. Those meeting eligibility criteria will be treated according to the treatment sequence assigned during randomization. Participants will view the standardized training video for the applicable product at the beginning of each treatment phase and have access to the Information for Use document (IFU) to review during each treatment phase. The total expected duration of subject participation is approximately 10 weeks. Participants will use the device assigned in treatment phase 1 overnight while sleeping for 4 weeks (28 days) before transitioning to the second assigned device in treatment phase 2. There will be a minimum washout period of 2 weeks (not to exceed 4 weeks) between treatment phases and a re-screening of eligibility criteria before the second phase. In both treatment phases, participants will independently place and remove the FEC (female external catheter) or FUP (Female Urinary Pouch) after standardized teaching is completed on the first day of the treatment phase. The primary objectives are to evaluate safety (skin injury) and efficacy (capture rate). Safety will be assessed using the Draize Scale and efficacy will be measured based on daily urine capture rate. Health Care Providers (HCPs) will visit participants' homes daily to perform a skin assessment and collect urine measurements during the treatment phases. Participants will be withdrawn from the treatment phase if grade 4 is achieved in any category on the Draize skin irritation scale. The secondary objectives are to assess quality of life, tolerability, comfort and ease of use. Quality of life and comfort and ease of use will be measured using self-reported changes in quality of life via the validated Nocturia Quality of Life (N-Qol) tool and subjective evaluation of the therapy via participant survey, respectively. Tolerability will be measured by number of days of actual use of both devices, and discontinuation rate attributed to the device's discomfort or inconvenience. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02600676 -
Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis
|
N/A | |
Completed |
NCT04191863 -
Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.
|
||
Recruiting |
NCT03199508 -
Clinical Values of Voiding Diary for Diagnosis and Treatment for Monosymptomatic Enuresis in Children
|
N/A | |
Recruiting |
NCT06135311 -
Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation for Treating Nocturnal Enuresis in Children
|
N/A | |
Completed |
NCT03047720 -
Scheduled Awakenings for the Treatment of Nocturnal Enuresis
|
N/A | |
Recruiting |
NCT05617664 -
Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
|
N/A | |
Completed |
NCT02328092 -
A Double-blind Randomized Clinical Trial on the Efficacy of Magnetic Sacral Roots Stimulation for the Treatment of NE
|
N/A | |
Completed |
NCT02068560 -
The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion
|
N/A | |
Withdrawn |
NCT02337413 -
Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis
|
Phase 4 | |
Completed |
NCT01368913 -
MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis
|
N/A | |
Terminated |
NCT04420585 -
Desmopressin for Bedwetting in Children With SCD
|
Phase 4 | |
Completed |
NCT02538302 -
Minirin Versus Oxybutynin for Nocturnal Enuresis in Children
|
Phase 3 | |
Recruiting |
NCT04676139 -
The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children
|
Phase 3 | |
Completed |
NCT03812094 -
Basic Bladder Advice and Alarm Therapy in Nocturnal Enuresis
|
N/A | |
Recruiting |
NCT03477812 -
Sleep and Nocturnal Enuresis: Ambulatory Polysomnographic Study
|
||
Completed |
NCT02178826 -
Nocturnal Enuresis and Rapid Maxillary Expansion
|
N/A | |
Recruiting |
NCT01575678 -
The Effect of Melatonin on Nocturnal Enuresis
|
Phase 2 | |
Completed |
NCT01078753 -
Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis
|
Phase 3 | |
Recruiting |
NCT04313192 -
TENS Treatment for Bedwetting
|
N/A | |
Completed |
NCT05178641 -
Overnight Pant Study for Children With Nocturnal Enuresis
|
N/A |